Type 1 diabetes mellitus with diabetic nephropathy
Methodology & AI Transparency ⓘ
Type 1 diabetes mellitus with diabetic nephropathy Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Type 1 diabetes mellitus with diabetic nephropathy—coded clinically as E10.21 across Diabetes & Glucose guidelines—combines urine microalbumin-to-creatinine ratios [Type 1 diabetes mellitus with diabetic nephropathy E10.21] with structured follow-up of Fasting Insulin [Type 1 diabetes mellitus with diabetic nephropathy E10.21] (3.0 – 7.0 uIU/mL (E10.21)).
- 2 Real-world patient consensus: Diagnostic registry E10.21: Type 1 diabetes mellitus with diabetic nephropathy is managed within Diabetes & Glucose.
- 3 Typical cash cost range: Differential triage of Type 1 diabetes mellitus with diabetic nephropathy (E10.21) utilizes urine microalbumin-to-creatinine ratios [Type 1 diabetes mellitus with diabetic nephropathy E10.21].
- 4 Top reported side effects / signs: Longitudinal Type 1 diabetes mellitus with diabetic nephropathy monitoring tracks Fasting Plasma Glucose [Type 1 diabetes mellitus with diabetic nephropathy E10.21] toward 75 – 95 mg/dL (E10.21).
Ask our AI Specialists anything about Type 1 diabetes mellitus with diabetic nephropathy
What Is Type 1 diabetes mellitus with diabetic nephropathy?
Type 1 diabetes mellitus with diabetic nephropathy—coded clinically as E10.21 across Diabetes & Glucose guidelines—combines urine microalbumin-to-creatinine ratios [Type 1 diabetes mellitus with diabetic nephropathy E10.21] with structured follow-up of Fasting Insulin [Type 1 diabetes mellitus with diabetic nephropathy E10.21] (3.0 – 7.0 uIU/mL (E10.21)).
Pathophysiology, Underlying Causes & Clinical Presentation
In Type 1 diabetes mellitus with diabetic nephropathy (E10.21), physiological disruption stems from advanced glycation end-product in Type 1 diabetes mellitus with diabetic nephropathy (E10.21: microvascular injury), informing Type 1 & Type 2 Diabetes protocols that track Fasting Insulin [Type 1 diabetes mellitus with diabetic nephropathy E10.21] (3.0 – 7.0 uIU/mL (E10.21)).
Common Symptoms & Clinical Signs
- • Presentation of Type 1 diabetes mellitus with diabetic nephropathy (E10.21): elevated fasting blood in Type 1 diabetes mellitus with diabetic nephropathy (E10.21: glucose or post-meal)
- • Secondary Type 1 diabetes mellitus with diabetic nephropathy clinical sign: increased thirst [Type 1 diabetes mellitus with diabetic nephropathy E10.21]
- • Symptom flares in Type 1 diabetes mellitus with diabetic nephropathy correlating with Fasting Plasma Glucose [Type 1 diabetes mellitus with diabetic nephropathy E10.21] deviation outside 75 – 95 mg/dL (E10.21)
- • Functional diabetes & glucose impact requiring urine microalbumin-to-creatinine ratios [Type 1 diabetes mellitus with diabetic nephropathy E10.21] evaluation (E10.21)
Type 1 diabetes mellitus with diabetic nephropathy Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E10.21 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NLM Clinical Tables |
| Diagnostic / Lab Marker: Fasting Plasma Glucose [Type 1 diabetes mellitus with diabetic nephropathy E10.21] | 75 – 95 mg/dL (E10.21) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Insulin [Type 1 diabetes mellitus with diabetic nephropathy E10.21] | 3.0 – 7.0 uIU/mL (E10.21) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CGM Time-in-Range (70–140 in Type 1 diabetes mellitus with diabetic nephropathy (E10.21: mg/dL)) | > 85% (E10.21) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Type 1 diabetes mellitus with diabetic nephropathy
Treatment selection for Type 1 diabetes mellitus with diabetic nephropathy depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Type 1 diabetes mellitus with diabetic nephropathy)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Randomized trials of telmisartan versus active controls for insulin resistance in: What a 2,033-Participant Study Found When data from all the 33 trials were pooled, telmisartan was associated with statistically significant reductions in percent changes of insulin levels (-10.92%; -15.60% to -6.23%; P < .00001) and HOMA-IR (-15.89%; -22.01% to... Journal of the American Society of Hypertension : JASH • 2014-08-15 • Meta-Analysis | N = 2,033 | 99/100 | PMID 25151319 ↗ |
| New Insights on Benefits and safety of empagliflozin as add-on to metformin for type 2: What a 4,256-Participant Study Found EMPA as add-on to MET was well tolerated and provided additional benefits beyond glucose lowering, such as weight loss and blood pressure reduction. European journal of clinical pharmacology • 2016-06-15 • Meta-Analysis | N = 4,256 | 99/100 | PMID 26832915 ↗ |
| New Insights on Is metformin still the most efficacious first-line oral hypoglycaemic drug in: What a 33,830-Participant Study Found This meta-analysis showed that repaglinide and metformin would be the most efficacious oral drugs for first-line single-drug treatment of T2DM. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2019-01-15 • Meta-Analysis | N = 33,830 | 99/100 | PMID 30230172 ↗ |
| New Insights on Heart and blood vessel outcomes of liraglutide in patients with type 2: What a 14,608-Participant Study Found Our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and heart and blood vessel death among patients with type 2 diabetes. Medicine • 2019-11-15 • Meta-Analysis | N = 14,608 | 99/100 | PMID 31725627 ↗ |
| New Insights on Urinary tract infections in patients with diabetes treated with: What a 3,152-Participant Study Found Treatment of type 2 diabetes with once-daily dapagliflozin 5 or 10mg is accompanied by a slightly increased risk of urinary tract infection. Journal of diabetes and its complications • 2013-01-15 • Meta-Analysis | N = 3,152 | 99/100 | PMID 23849632 ↗ |
Type 1 diabetes mellitus with diabetic nephropathy Patient Community & “People Like Me” Threads
Filter Type 1 diabetes mellitus with diabetic nephropathy community threads and patient logs by age, biological sex, dosage, and treatment duration.